Source-control register
Every guideline, NICE Technology Appraisal, NHS England commissioning policy, BAD specialty guideline, RCPath dataset, staging framework and high-impact trial that the monographs, calculators and cases rely on — in one place, with publication date, what we use it for, and when we last verified it. This page is the editorial provenance record. If a recommendation on the site cannot be traced to a row here, please flag it.
Verified
All entries last verified against the cited sources: 19 May 2026.
Targeted live-verification of NICE technology appraisal codes was repeated on 19 May 2026; rows or page references for previously circulating misattributions (including TA868 for pembrolizumab cSCC, TA718 / TA1077 for sonidegib, TA961 for adjuvant pembrolizumab IIB/IIC, TA871 for mogamulizumab, TA396 / TA414 / TA416 / TA417 BRAF-MEK attributions, and TA922 / TA1009 unrelated-code claims) have been corrected, removed or explicitly labelled as not applicable. Subsequent NICE publications, NHS England commissioning policy updates and BAD revisions may post-date this verification — always check the linked authoritative page for current wording. Routine re-verification is scheduled quarterly.
How to use this page
- Use the authority filter chips to narrow to NICE TAs, NICE clinical guidelines, NHS England commissioning policies, BAD, RCPath, staging frameworks, WHO classifications, or pivotal trials.
- The search box matches code, title, condition, drug name and the "what we use it for" column.
- Date is the original publication or last substantive update of the source — not the date we last checked it (that is recorded site-wide in the verification banner above).
- Cited on lists the principal pages where the source is invoked. The list is illustrative; deep cross-references are intentionally not exhaustive.
- Rows tinted in the terracotta accent are NICE appraisals that were terminated (no positive recommendation) — included for traceability so readers can see we have not silently dropped the reference.
| Authority | Code | Title | Source date | What we use it for | Cited on |
|---|---|---|---|---|---|
| NICE clinical guidelines | |||||
| NICE NG | NG14 | Melanoma: assessment and management | Published 29 Jul 2015; last updated 27 Jul 2022 | Diagnostic pathway, BRAF analysis, SLNB indications, excision margins, stage-specific management, and the §1.9.15 follow-up table that drives the melanoma branch of the follow-up scheduler. | Melanoma · Follow-up · Staging tool |
| NICE NG | NG12 | Suspected cancer: recognition and referral | Published 23 Jun 2015; last updated 15 Apr 2026 | 2-week-wait skin-cancer referral criteria, including the weighted 7-point checklist (score ≥ 3) for suspected melanoma and the cSCC urgent-referral wording. | 2WW checker · Topics |
| NICE NG | CSG9 | Improving outcomes for people with sarcoma | Published 20 Mar 2006; last reviewed 8 Oct 2014 | Sarcoma service organisation: prompt expert diagnosis, specialist sarcoma MDT management and specialist surgery. Used when cutaneous sarcoma / DFSP presentations need regional sarcoma MDT input alongside the skin-cancer MDT. | DFSP · AFX |
| NICE NG | NG101 | Early and locally advanced breast cancer: diagnosis and management | Published 18 Jul 2018; last updated 14 Apr 2025 | Cross-referenced for cutaneous metastases of breast cancer (carcinoma erysipeloides, en cuirasse) and for cross-recognition of dermatomyositis paraneoplastic associations. | Cutaneous metastases |
| NICE Technology Appraisals — melanoma | |||||
| NICE TA | TA319 | Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma | 2014 | First-line ipilimumab monotherapy (largely superseded by combination immunotherapy; included for historical context and where combination ICI contraindicated). | Melanoma · Ipilimumab |
| NICE TA | TA366 | Pembrolizumab for advanced melanoma not previously treated with ipilimumab | 2015 | First-line pembrolizumab monotherapy in advanced (unresectable or metastatic) melanoma. | Melanoma · Pembrolizumab |
| NICE TA | TA384 | Nivolumab for treating advanced (unresectable or metastatic) melanoma | 2016 | Anti-PD-1 monotherapy alternative to pembrolizumab in advanced melanoma. | Melanoma · Nivolumab |
| NICE TA | TA396 | Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma | 2016 | BRAF + MEK inhibitor combination for metastatic BRAF V600-mutant melanoma — the principal active NICE-recommended targeted regimen. | Melanoma · Dabrafenib + trametinib |
| NICE TA Not recommended | TA414 | Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma | 2016 — not recommended | NICE did not recommend cobimetinib + vemurafenib for routine NHS use in advanced BRAF V600 melanoma. Retained here for traceability; the alternative BRAF + MEK pairs (dabrafenib + trametinib, TA396; encorafenib + binimetinib, TA562) are the NHS-funded options. | Melanoma |
| NICE TA | TA400 | Nivolumab in combination with ipilimumab for treating advanced melanoma | 2016 | Dual ICI combination — longest median overall survival in multiple phase III trials; first-line option in fit patients. | Melanoma · Ipilimumab · Nivolumab |
| NICE TA | TA410 | Talimogene laherparepvec (T-VEC) for treating unresectable metastatic melanoma | 2016 | Intralesional oncolytic herpes-virus therapy for unresectable cutaneous, subcutaneous and nodal melanoma metastases (OPTiM trial evidence). | T-VEC · Melanoma |
| NICE TA | TA321 | Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (monotherapy) | 2014 | BRAF inhibitor monotherapy — superseded by combination BRAF + MEK regimens (TA396); not contemporary standard. Retained for historic / contraindication reference. | Melanoma · Dabrafenib + trametinib |
| NICE TA | TA544 | Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma | 2018 | Adjuvant BRAF + MEK targeted therapy for completely resected stage III BRAF-mutant melanoma — 12 months. | Melanoma · Dabrafenib + trametinib · Follow-up |
| NICE TA | TA562 | Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma | 2019 | Alternative BRAF + MEK pair to dabrafenib/trametinib in advanced disease; slightly different toxicity profile. | Encorafenib + binimetinib · Melanoma |
| NICE TA | TA684 | Nivolumab for adjuvant treatment of completely resected stage 3 or 4 melanoma | 2021 | Adjuvant anti-PD-1 alternative to pembrolizumab for resected stage III or IV melanoma — 12 months. | Melanoma · Nivolumab · Follow-up · Acral case |
| NICE TA | TA766 | Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma | February 2022 | Adjuvant anti-PD-1 for resected stage III melanoma (microscopic / SLNB-detected and macroscopic, in the absence of URN 2426 neoadjuvant pathway eligibility). | Melanoma · Pembrolizumab · Follow-up · Acral case |
| NICE TA | TA837 | Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma | October 2022 | Adjuvant anti-PD-1 for completely resected stage IIB / IIC melanoma — 12 months. | Melanoma · Pembrolizumab · Follow-up |
| NICE TA | TA950 | Nivolumab with relatlimab for untreated advanced melanoma | 2024 | Anti-PD-1 + anti-LAG-3 fixed-dose combination for first-line advanced melanoma — emerging option with single-agent ICI toxicity profile. | Melanoma · Nivolumab |
| NICE TA | TA1027 | Tebentafusp for treating advanced uveal melanoma | Published 9 Jan 2025 | Bispecific HLA-A*02:01-restricted gp100 / CD3 T-cell engager for HLA-A*02:01-positive untreated metastatic uveal melanoma — first agent to extend overall survival in this setting. | Uveal melanoma · Melanoma |
| NICE Technology Appraisals — cutaneous squamous cell carcinoma | |||||
| NICE TA | TA802 | Cemiplimab for treating advanced cutaneous squamous cell carcinoma | Published 29 June 2022 (replaced TA592, 2019) | First-line anti-PD-1 monotherapy for advanced cSCC not suitable for curative surgery or radiotherapy. The only NICE-approved systemic option for advanced cSCC. | Cemiplimab · cSCC · Lip ulcer case |
| NICE in development | GID-TA11582 / ID6473 | Pembrolizumab with platinum-based chemotherapy for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma | NICE evaluation in development — no final TA at the date of last verification | Signposted so clinicians know the future direction. Not yet commissioned. The current NICE-approved systemic option for advanced cSCC remains cemiplimab (TA802). | Pembrolizumab · cSCC |
| NICE Technology Appraisals — basal cell carcinoma | |||||
| NICE TA Not recommended | TA489 | Vismodegib for treating basal cell carcinoma | 2017 — not recommended | NICE did not recommend vismodegib for routine NHS use in locally advanced or metastatic BCC. Retained here for traceability. It is not a routine NHS-commissioned option; any use needs specialist MDT and current NHS England / local funding or IFR confirmation. | Vismodegib · BCC · Gorlin syndrome |
| NICE Technology Appraisals — Merkel cell carcinoma | |||||
| NICE TA | TA691 | Avelumab for untreated metastatic Merkel cell carcinoma | 2021 | Anti-PD-L1 first-line therapy for untreated metastatic MCC; durable responses reported. TA517 records the earlier metastatic-MCC appraisal history. | Avelumab · Merkel cell carcinoma |
| NICE Technology Appraisals — cutaneous lymphoma and adjacent haematology | |||||
| NICE TA | TA577 | Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma | 2019 | Anti-CD30 antibody-drug conjugate for relapsed / refractory CD30+ CTCL. | Brentuximab vedotin · Cutaneous lymphoma |
| NICE TA | TA720 | Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma | 2021 | Topical chlormethine (mechlorethamine) gel for adults with stage IA–IIA mycosis fungoides. | Cutaneous lymphoma |
| NICE TA | TA754 | Mogamulizumab for treating mycosis fungoides and Sézary syndrome | 2021 | Anti-CCR4 monoclonal antibody for relapsed / refractory mycosis fungoides and Sézary syndrome. | Cutaneous lymphoma |
| NICE TA Terminated | TA782 | Tagraxofusp for treating untreated blastic plasmacytoid dendritic cell neoplasm | Terminated appraisal (2023) | NICE appraisal of tagraxofusp (Elzonris) for first-line BPDCN was terminated — i.e. no positive NICE recommendation. Any UK use should be confirmed through specialist haematology MDT and current local / specialist funding, IFR, clinical-trial or compassionate-use routes. Cited for transparency; do not interpret as NICE-approved. | BPDCN |
| NICE Technology Appraisals — adjacent oncology used as context on skin pages | |||||
| NICE TA | TA661 | Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma | 2020 | Adjacent (non-skin) NICE indication for pembrolizumab in mucosal HNSCC — referenced as context on the pembrolizumab monograph for clinicians who manage both cutaneous and mucosal head-and-neck disease. | Pembrolizumab |
| NICE TA | TA1145 | Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma | Published 21 April 2026 | Adjacent (non-skin) NICE indication for pembrolizumab in mucosal HNSCC with PD-L1 CPS ≥ 1. | Pembrolizumab |
| NICE TA | TA392 | Adalimumab for treating moderate to severe hidradenitis suppurativa | 2016 | Biologic for long-term HS control — relevant where chronic HS is the substrate for HS-associated cSCC (Marjolin-type transformation). | HS-associated cSCC |
| NICE TA | TA539 | Lutetium-177 (¹⁷⁷Lu) DOTATATE for advanced gastroenteropancreatic neuroendocrine tumours | 2018 | Peptide-receptor radionuclide therapy — cited on the paraneoplastic dermatosis context for necrolytic migratory erythema (glucagonoma). | Necrolytic migratory erythema |
| NICE TA | TA630 | Larotrectinib for treating NTRK fusion-positive solid tumours | 2020 | Selective TRK inhibitor for NTRK-fusion sarcomas including cutaneous / soft-tissue NTRK-fusion spindle-cell neoplasm. NICE TA630 is a Cancer Drugs Fund / managed-access recommendation, so current NICE / NHS England status should be checked before treatment. | NTRK-fusion sarcoma |
| NICE TA | TA873 | Cannabidiol with clobazam for treating seizures associated with tuberous sclerosis complex | 2023 | Anticonvulsant in TSC-associated drug-resistant epilepsy. TSC is the principal cancer-predisposition syndrome cross-referenced on the site (cutaneous angiofibromas, hypomelanotic macules, shagreen patch, periungual fibromas, renal AML, SEGA). | Tuberous sclerosis |
| NICE TA | TA644 | Entrectinib for treating NTRK fusion-positive solid tumours | 2020 | Historical CDF guidance only. TA644 has been replaced by TA1118, which terminated the appraisal without a positive NHS recommendation for NTRK fusion-positive solid tumours. | NTRK-fusion sarcoma |
| NICE TA | TA1118 | Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal) | 2026 | Current NICE position replacing TA644: no recommendation for NHS use because the appraisal was terminated. Existing patients may continue until they and their NHS clinician decide when best to stop. | NTRK-fusion sarcoma |
| NICE Highly Specialised Technologies (HST) | |||||
| NICE HST | HST20 | Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over | 2022 | MEK inhibitor for symptomatic inoperable plexiform NF in paediatric NF1 — the only HST-route appraisal cited on the site. | Neurofibromatosis 1 |
| NICE Interventional Procedure Guidance (IPG) | |||||
| NICE IPG | IPG155 | Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions) | 2006 | Procedural guidance for PDT in actinic keratosis, Bowen's disease and superficial BCC. | PDT · Actinic keratosis · Bowen's disease |
| NICE IPG | IPG446 | Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma | 2013 | Procedural guidance for electrochemotherapy of skin metastases from non-skin primary tumours and melanoma. It should not be cited as NICE endorsement for primary BCC. | Cutaneous metastases · Melanoma (in-transit) |
| NHS England commissioning policies | |||||
| NHS England | URN 2426 | Neo-adjuvant followed by adjuvant pembrolizumab for stage III macroscopic resectable melanoma (> 12 years) | Published 28 Apr 2026 | Off-label pembrolizumab regimen: 3 neoadjuvant doses (3-weekly) before complete resection + therapeutic lymph node dissection, then adjuvant pembrolizumab to complete 54 weeks total (adults: 15 further 3-weekly treatments or 7 further 6-weekly treatments). Eligibility: macroscopic resectable stage IIIB / IIIC / IIID, age ≥ 12, ECOG 0–1; microscopic SLNB-detected disease excluded. Evidence base: SWOG S1801 (Patel NEJM 2023). | Pembrolizumab · Melanoma · Acral case · Follow-up · Guidelines hub |
| British Association of Dermatologists (BAD) specialty guidelines | |||||
| BAD | BAD cSCC 2020 | British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020 | 2020 | Primary source for cSCC margins (4 mm low-risk; 6–10 mm or Mohs for high-risk), BWH risk-factor wording (incl. the three high-risk PNI criteria), nodal imaging thresholds, and adjuvant-RT indications. | cSCC · cSCC staging tool · Margin planner · Follow-up |
| BAD | BAD BCC 2021 | BAD guidelines for the management of basal cell carcinoma 2021 | 2021 | BCC risk-stratification, Mohs indications, follow-up cadence and incompletely-excised high-risk BCC management. | BCC · Margin planner · Follow-up |
| Royal College of Pathologists (RCPath) cancer datasets | |||||
| RCPath | G125 | Dataset for histopathological reporting of primary cutaneous malignant melanoma | February 2019; hub notes currently on hold; TNM 9 appendix November 2025 | Minimum data items for UK melanoma pathology reports: Breslow, ulceration, mitotic rate, LVI, microsatellites, margin clearance, tumour subtype. NICE NG14 treatment pathways remain based on AJCC 8 / UICC TNM 8 staging. | Melanoma · Staging tool |
| RCPath | G124 | Dataset for histopathological reporting of primary cutaneous squamous cell carcinoma | February 2019 | Minimum data items for cSCC reports: differentiation grade, depth, PNI features (calibre, depth, named nerve), LVI, margin clearance, subtype. | cSCC · cSCC staging tool |
| RCPath | G123 | Dataset for histopathological reporting of primary cutaneous basal cell carcinoma | February 2019 | Minimum data items for BCC reports: subtype (nodular / superficial / infiltrative / morphoeic / micronodular / basosquamous), margin clearance, PNI. | BCC |
| RCPath | G126 | Dataset for histopathological reporting of Merkel cell carcinoma | February 2019 | CK20 dot-pattern, MCPyV status, tumour thickness, LVI, depth and margin reporting standards. | Merkel cell |
| RCPath | RCPath STS | Dataset for histopathological reporting of soft-tissue sarcomas (DFSP, AFX, PDS, leiomyosarcoma, angiosarcoma) | Current edition | Cutaneous and soft-tissue sarcoma reporting standards covering DFSP (incl. fibrosarcomatous transformation), atypical fibroxanthoma vs pleomorphic dermal sarcoma, and cutaneous angiosarcoma. | DFSP · AFX |
| Staging frameworks | |||||
| Staging | AJCC 8 (melanoma) | American Joint Committee on Cancer melanoma staging system, 8th edition — Gershenwald JE et al. | CA Cancer J Clin 2017;67:472–92 | Definitive T / N / M categories and stage groupings (0 → IV) used by the melanoma staging calculator. NG14 explicitly adopts AJCC 8 / UICC TNM 8. | Melanoma staging tool · Melanoma · all case studies |
| Staging | AJCC 8 (cSCC) | American Joint Committee on Cancer head & neck cSCC staging, 8th edition | 2017 | Site-specific (head & neck) cSCC T-staging. Surfaced alongside BWH on the cSCC staging tool; NG14 / BAD prefer BWH for prognostic discrimination in most cohorts. | cSCC staging tool · cSCC |
| Staging | UICC TNM 8 | Union for International Cancer Control TNM classification of malignant tumours, 8th edition | 2017 | UK NHS-adopted TNM framework (NG14 §"Stages of melanoma" cites UICC TNM 8 alongside AJCC 8). | Melanoma staging tool · cSCC staging tool |
| Staging | BWH (cSCC) | Brigham & Women's Hospital cSCC T-stage — Jambusaria-Pahlajani A et al. | JAMA Dermatol 2013;149:402–10 | Four-factor BWH T-stage (diameter ≥ 2 cm, poor differentiation, high-risk PNI, invasion beyond fat; bone → T3). BAD 2020 endorses BWH for prognostic discrimination over AJCC 8 in most cohorts. | cSCC staging tool · cSCC · Lip ulcer case |
| WHO Classifications of Tumours | |||||
| WHO | WHO Skin (5e) | Skin Tumours, WHO Classification of Tumours, 5th edition, volume 12 | 2025 | Authoritative taxonomy for cutaneous tumours — used throughout the monographs for nomenclature, subtype boundaries (e.g. AFX vs PDS, micronodular vs morphoeic BCC) and biomarker definitions. | Topics · all monographs |
| WHO | WHO Haem (5e) | WHO Classification of Haematolymphoid Tumours, 5th edition | 2022 | Current taxonomy for primary cutaneous lymphomas (mycosis fungoides, Sézary syndrome, primary cutaneous CD30+ LPDs, ATLL, NK/T-cell lymphomas) and BPDCN. | Cutaneous lymphoma · BPDCN · ATLL |
| WHO | WHO STB (5e) | WHO Classification of Soft Tissue and Bone Tumours, 5th edition | 2020 | Soft-tissue taxonomy underpinning DFSP, atypical fibroxanthoma, pleomorphic dermal sarcoma, leiomyosarcoma, angiosarcoma and the NTRK-fusion spindle-cell neoplasm. | DFSP · AFX · NTRK-fusion sarcoma |
| WHO | WHO / modern LCH taxonomy | Langerhans cell histiocytosis as a clonal histiocytic / dendritic-cell neoplasm | 2016 | Frames LCH as a clonal MAPK-driven histiocytic / dendritic-cell neoplasm rather than a reactive disorder; supports the targeted-therapy framing on the LCH monograph. | Langerhans cell histiocytosis |
| Pivotal trials supporting practice-changing claims | |||||
| Trial | KEYNOTE-054 | Eggermont AMM et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma | N Engl J Med 2018 | Pivotal trial underpinning TA766 (adjuvant pembrolizumab, resected stage III). | Pembrolizumab · Melanoma |
| Trial | KEYNOTE-716 | Luke JJ et al. Pembrolizumab versus placebo in adjuvant stage IIB / IIC melanoma | Lancet 2022 | Pivotal trial underpinning TA837 (adjuvant pembrolizumab, resected stage IIB / IIC). | Pembrolizumab · Melanoma |
| Trial | SWOG S1801 | Patel SP et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma | N Engl J Med 2023;388(9):813–823 | Phase II, open-label, 313-patient RCT showing 2-year event-free survival 72% (neoadj-adj) vs 49% (adj-only); difference 23%, p = 0.0045. Evidence base for NHS England URN 2426. | Pembrolizumab (URN 2426 section) |
| Trial | MSLT-II | Faries MB et al. Completion dissection or observation for sentinel-node metastasis in melanoma | N Engl J Med 2017 | Practice-changing trial — no survival benefit for completion lymphadenectomy after SLN-positive disease; ultrasound surveillance + adjuvant systemic therapy is the modern standard. Underpins NG14 §1.6.1. | Melanoma · Acral case |
| Trial | OPTiM | Andtbacka RHI et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma | J Clin Oncol 2015 | Pivotal phase III trial supporting NICE TA410 for T-VEC in unresectable cutaneous and nodal metastases. | T-VEC |
| Trial | SPRINT | Gross AM et al. Selumetinib in children with inoperable plexiform neurofibromas | N Engl J Med 2020 | Pivotal phase II trial supporting NICE HST20 (selumetinib for paediatric NF1 plexiform NF). | NF1 |
| Trial | IMCgp100-202 | Nathan P et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma | N Engl J Med 2021 | First systemic therapy to extend overall survival in metastatic uveal melanoma; evidence base for TA1027. | Uveal melanoma |
Editorial governance for this register
- What counts as a source. A published authoritative document — NICE NG / TA / IPG / HST / QS, NHS England commissioning policy, BAD / BSDS / BAPRAS / RCR guideline, RCPath cancer dataset, AJCC / TNM / WHO classification, or a phase II / III randomised trial cited directly to support a practice claim. Editorial opinion, anecdote and "common practice" assertions are not sources and should not be added to this register.
- Quarterly re-verification. The editorial team re-runs every link, re-checks the publication date and confirms the recommendation wording against the source. The verification-date banner at the top of this page is updated accordingly.
- Terminated NICE appraisals are retained. If a NICE appraisal is terminated (no positive recommendation) we keep the row, tag it "Terminated", and explain the actual UK access route. We do not silently drop terminated appraisals because doing so makes the change history harder to audit.
- If you spot a discrepancy between a claim on the site and the cited source, please email the editor. The site's clinical credibility depends on every recommendation being traceable to a row here.